Navigation Links
Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Date:4/26/2012

w product launched in the first quarter was Escitalopram Tablets USP, 5 mg, 10 mg and 20 mg, the first equivalent product to Forest Laboratories' Lexapro®, which is used for acute and maintenance treatment of major depressive disorder and acute treatment of generalized anxiety disorder. The increase in sales from new products was partially offset by lower sales of existing products, principally as a result of lower volumes. The effect of foreign currency translation was insignificant within North America.

Third party net revenues from EMEA were $335.6 million for the quarter ended March 31, 2012, compared to $389.1 million for the comparable prior year period, a decrease of $53.5 million, or 13.7%. Translating current quarter third party net revenues from EMEA at prior year comparative period exchange rates would have resulted in a decline in third party net revenues, excluding the effect of foreign currency, of approximately $39 million, or 10%. This decrease was mainly the result of competitive markets conditions which resulted in unfavorable pricing and volume in many of the European markets in which Mylan operates, partially offset by new product launches throughout the region and increased volume in Italy.

Third party net revenues in Asia Pacific were $298.7 million for the quarter ended March 31, 2012, compared to $276.1 million for the comparable prior year period, an increase of $22.6 million, or 8.2%. Foreign currency translation had a negative impact on sales for the current quarter. Excluding the effect of foreign currency, calculated as described above, the increase was approximately $32 million, or 12%. This increase is primarily driven by higher third party sales from at Mylan Laboratories Limited (formerly Matrix Laboratories Limited), Mylan's subsidiary in India, as a result of an increase in sales of anti-retroviral finished dosage form generic products, which are used in the treatment of HIV/AIDS, as well as higher third-party s
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
2. Mylan Launches Generic Version of Zyprexa® Tablets
3. Mylan Launches First Generic Version of Lescol® Capsules
4. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
5. Mylan One of First to Launch Generic Version of Boniva®
6. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
7. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
8. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
9. Mylan Secures an Additional $300 Million of Committed Financing
10. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
11. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... , Sept. 16, 2014 Surgeons at ... describe in a case report the first successful use ... a 13- year-old boy with failing Fontan circulation to ... he was 3 years old, the patient received a ... as functional single ventricle. "The Fontan operation is the ...
(Date:9/16/2014)... Research and Markets has ... Devices Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth ... laparoscopic devices. The report provides a ... applications and industry chain structure. The laparoscopic devices ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Global Laparoscopy Devices Industry Report 2014 2
... 23, 2011 The U.S. Food and Drug Administration ... active ulcerative colitis (UC) in children older than 6 ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... induces and maintains clinical remission in these patients. ...
... ANN ARBOR, Mich., Sept. 23, 2011 Adapting adult medical ... often problematic practice across U.S. hospitals. At the ... and researchers who care for children have been leading the ... test medical devices and curb problems that come from using ...
Cached Medicine Technology:FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 2FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 2University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 4
(Date:9/16/2014)... Centre, NY (PRWEB) September 16, 2014 ... product manufactured by Johnson & Johnson subsidiary Ethicon concluded ... of plaintiff Jo Huskey and awarding her $3.27 million ... According to the Reuters report, “jurors found Ethicon liable ... and their doctors that users were at risk from ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
(Date:9/16/2014)... September 16, 2014 Duke’s Chowder House ... Rebls and Gratafy for a fun evening ... hub is firmly cemented. With the growth of companies in these ... for people who work in tech and at startups to connect ... Gratafy are happy to host events for their peers to meet ...
(Date:9/16/2014)... Treatment with endocrine therapy and radiation therapy as ... of care for women with hormone-receptor positive (HR+) ... at Fox Chase Cancer Center, however, shows that ... populations with the disease. , The results, ... Society for Radiation Oncology,s 56th Annual Meeting on ...
(Date:9/16/2014)... 16, 2014 This year’s theme is ... Sustainable company Glen Mills, Pennsylvania, September 15, 2014- Holganix, ... of the fastest growing companies in the country, produces ... shrub, and tree health-care by naturally decreasing disease and ... Today it announced that it will hold its third ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... who don,t metabolize drug well, , FRIDAY, March 12 (HealthDay ... "black box" warning on its label, alerting patients and doctors ... officials said Friday. , Patients with a certain genetic variation ... puts them at risk for heart attack and stroke, the ...
... with a known sex offender is beginning to settle in as a dark, dark corner of the landscape of life. Slowly we are taking up our routines again, changed by ... ... ... ...
... released the following statement.  , ... , , ... ... "We applaud the steps taken by the Congressional Black Caucus and the White House to meet to discuss the ...
... , ... , ... ... ST. LOUIS , March 12 More than 200 Teamsters and religious leaders held a rally and prayer vigil at Ascension ...
... Award Presented to Joel A. Gingras, Jr. Memorial Fund , ... , , ... ... CHICAGO , March 12 The American Brain Tumor Association (ABTA) presented its first ...
... profitable and industry-leading corporation, LIMU, based in Florida , today announced a brand transformation for 2010.   With ... upcoming international convention March 19 – 20, 2010 in Dallas, Texas . , ... ... , ...
Cached Medicine News:Health News:Plavix Less Effective in Some Patients 2Health News:Plavix Less Effective in Some Patients 3Health News:TypeAMom.net on Keeping Daughters Safe From Predators 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 3Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 4Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 5Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 6Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 7Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 8Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 2Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 3Health News:LIMU Accelerates Growth Era With Brand Transformation 2Health News:LIMU Accelerates Growth Era With Brand Transformation 3
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: